Barclays’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,973
| Closed | -$503K | – | 5037 |
|
|
2020
Q4 | $503K | Hold |
1,973
| – | – | ﹤0.01% | 3229 |
|
|
2020
Q3 | $491K | Hold |
1,973
| – | – | ﹤0.01% | 3242 |
|
|
2020
Q2 | $686K | Sell |
1,973
-8,160
| -81% | -$2.55M | ﹤0.01% | 3071 |
|
|
2020
Q1 | $2.71M | Buy |
10,133
+280
| +3% | +$86.6K | ﹤0.01% | 2001 |
|
|
2019
Q4 | $3.19M | Buy |
9,853
+5,593
| +131% | +$1.62M | ﹤0.01% | 2493 |
|
|
2019
Q3 | $1.16M | Sell |
4,260
-1,447
| -25% | -$531K | ﹤0.01% | 3512 |
|
|
2019
Q2 | $3.05M | Buy |
5,707
+2,567
| +82% | +$1.29M | ﹤0.01% | 2417 |
|
|
2019
Q1 | $1.58M | Buy |
3,140
+833
| +36% | +$494K | ﹤0.01% | 2846 |
|
|
2018
Q4 | $1.14M | Sell |
2,307
-7,660
| -77% | -$4.62M | ﹤0.01% | 2980 |
|
|
2018
Q3 | $9.11M | Buy |
9,967
+3,347
| +51% | +$2.86M | 0.01% | 1321 |
|
|
2018
Q2 | $4.85M | Buy |
6,620
+6,167
| +1,361% | +$7.11M | ﹤0.01% | 1750 |
|
|
2018
Q1 | $723K | Sell |
453
-1,494
| -77% | -$1.92M | ﹤0.01% | 3575 |
|
|
2017
Q4 | $1.74M | Buy |
1,947
+287
| +17% | +$170K | ﹤0.01% | 2562 |
|
|
2017
Q3 | $598K | Buy |
1,660
+380
| +30% | +$119K | ﹤0.01% | 3445 |
|
|
2017
Q2 | $375K | Sell |
1,280
-3,940
| -75% | -$1.14M | ﹤0.01% | 3806 |
|
|
2017
Q1 | $1.84M | Buy |
5,220
+4,727
| +959% | +$1.06M | ﹤0.01% | 2171 |
|
|
2016
Q4 | $91K | Buy |
493
+206
| +72% | +$41.9K | ﹤0.01% | 4811 |
|
|
2016
Q3 | $74K | Buy |
287
+200
| +230% | +$51.5K | ﹤0.01% | 4726 |
|
|
2016
Q2 | $18K | Buy |
87
+20
| +30% | +$4.47K | ﹤0.01% | 5319 |
|
|
2016
Q1 | $13K | Sell |
67
-640
| -91% | -$123K | ﹤0.01% | 5393 |
|
|
2015
Q4 | $170K | Buy |
707
+100
| +16% | +$20.6K | ﹤0.01% | 4032 |
|
|
2015
Q3 | $91K | Sell |
607
-1,586
| -72% | -$281K | ﹤0.01% | 4681 |
|
|
2015
Q2 | $395K | Sell |
2,193
-5,894
| -73% | -$1.01M | ﹤0.01% | 3666 |
|
|
2015
Q1 | $1.33M | Buy |
8,087
+6,060
| +299% | +$1.25M | ﹤0.01% | 2708 |
|
|
2014
Q4 | $456K | Sell |
2,027
-313
| -13% | -$66.9K | ﹤0.01% | 3947 |
|
|
2014
Q3 | $421K | Buy |
2,340
+800
| +52% | +$153K | ﹤0.01% | 4092 |
|
|
2014
Q2 | $277K | Buy |
1,540
+847
| +122% | +$150K | ﹤0.01% | 4507 |
|
|
2014
Q1 | $125K | Sell |
693
-807
| -54% | -$160K | ﹤0.01% | 5251 |
|
|
2013
Q4 | $248K | Sell |
1,500
-9,800
| -87% | -$1.58M | ﹤0.01% | 4801 |
|
|
2013
Q3 | $1.7M | Buy |
11,300
+10,933
| +2,979% | +$2.02M | ﹤0.01% | 2782 |
|
|
2013
Q2 | $64K | Buy |
+367
| New | +$56.3K | ﹤0.01% | 6131 |
|
Other funds holding NKTR
TSC
BI
VPC
Barclays's NKTR Position: Q2 2026 in Review
Barclays increased its Nektar Therapeutics (NKTR) stake by 711% in Q2 2026, buying an estimated $16.8M and bringing the position to 262,362 shares worth $18.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1177.
Barclays first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $30.2M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.
- Barclays held 262,362 shares of Nektar Therapeutics worth $18.3M as of Q2 2026.
- Barclays bought 230,006 Nektar Therapeutics shares in Q2 2026, an estimated $16.8M.
- Nektar Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1177 holding.
- Barclays first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Barclays's Nektar Therapeutics position peaked at $30.2M in Q1 2018.
- 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.